---
title: "QYUNS-B: QX004N enters Phase III clinical trial and receives payment from HANSOH PHARMA"
description: "QYUNS-B announced that its interleukin 23p19 inhibitor QX004N has entered Phase III clinical trials and has signed an exclusive licensing agreement with HANSOH PHARMA, covering research and developmen"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/251623179.md"
published_at: "2025-08-05T11:12:04.000Z"
---

# QYUNS-B: QX004N enters Phase III clinical trial and receives payment from HANSOH PHARMA

> QYUNS-B announced that its interleukin 23p19 inhibitor QX004N has entered Phase III clinical trials and has signed an exclusive licensing agreement with HANSOH PHARMA, covering research and development, production, and commercialization in mainland China, Taiwan, Hong Kong, and Macau. The company has received milestone and other payments of RMB 58 million from HANSOH PHARMA

According to the Zhitong Finance APP, QYUNS-B (02509) announced that the company is developing an interleukin 23p19 subunit (IL23p19) inhibitor QX004N for the treatment of psoriasis (Ps) and Crohn's disease (CD). In April 2024, the company signed an exclusive external licensing agreement with HANSOH PHARMA GROUP CO., LTD. (03692.HK) through its wholly-owned subsidiary HANSOH (Shanghai) Health Technology Co., Ltd. for the research and development, production, and commercialization of QX004N in mainland China, Taiwan, Hong Kong, and Macau.

The announcement stated that QX004N has recently entered Phase III clinical trials, becoming the fourth product in the company's pipeline to successfully enter the Phase III stage.

Recently, the company has received milestone and other payments totaling RMB 58 million from HANSOH PHARMA under the licensing agreement for the Phase III trial of Ps

### Related Stocks

- [02509.HK - QYUNS-B](https://longbridge.com/en/quote/02509.HK.md)
- [03692.HK - HANSOH PHARMA](https://longbridge.com/en/quote/03692.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$37.87 From HK$35.50, Keeps at Neutral | Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$37.87 From HK$35.50, Keeps at Neutral | [Link](https://longbridge.com/en/news/276056784.md) |
| Short Interest in Alstom ADR (OTCMKTS:ALSMY) Increases By 28.8% | Alstom ADR (OTCMKTS:ALSMY) experienced a significant increase in short interest, rising by 28.8% in January, totaling 47 | [Link](https://longbridge.com/en/news/276036662.md) |
| Mankind Pharma Says Tax Penalty Of 4.6 Million Rupees Dropped | Mankind Pharma Ltd :MANKIND PHARMA - TAX PENALTY OF 4.6 MILLION RUPEES DROPPED | [Link](https://longbridge.com/en/news/276062229.md) |
| Alibaba (BABA) Upgrades Qwen AI Model as China's Tech Giants Battle for Users | Alibaba has upgraded its AI model to Qwen3.5, enhancing its capabilities in text, image, and video processing. This move | [Link](https://longbridge.com/en/news/276055492.md) |
| Alibaba unveils new Qwen3.5 model for 'agentic AI era' | Alibaba has launched its new AI model, Qwen 3.5, which is designed for independent task execution and boasts significant | [Link](https://longbridge.com/en/news/276045126.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.